Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02601625 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02601625: Completed Phase 1 study, sponsored by AstraZeneca.
NCT02601625 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02601625, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy subjects
Primary Outcome
To evaluate Cmax of anifrolumab after single administration of two doses subcutaneously and one dose intravenously. Up to 13 blood samples were collected in total.
Interventions
- DRUG Anifrolumab SC injection (300mg)
- DRUG Anifrolumab IV infusion (300mg)
- DRUG Anifrolumab SC infusion (600mg)
- DRUG Anifrolumab placebo SC injection (300mg)
- DRUG Anifrolumab placebo IV infusion (300mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-11-16 |
| Est. Completion | 2016-05-25 |
| Phase | Phase 1 |
What the finished NCT02601625 record still lists
NCT02601625 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 5 interventions - of which Anifrolumab SC injection (300mg) is the first listed.
NCT02601625 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02601625 about?
NCT02601625 is a clinical study titled "A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects". This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy subjects
What is the current status of trial NCT02601625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-11-16. Estimated completion is 2016-05-25.
What interventions are being tested in trial NCT02601625?
The interventions under investigation include: Anifrolumab SC injection (300mg) (DRUG), Anifrolumab IV infusion (300mg) (DRUG), Anifrolumab SC infusion (600mg) (DRUG), Anifrolumab placebo SC injection (300mg) (DRUG), Anifrolumab placebo IV infusion (300mg) (DRUG).
Who is sponsoring clinical trial NCT02601625?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02601625's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI